Cancan Diagnostic is thrilled to unveil K9-LiquiDX, the world’s inaugural Minimal Residual Disease (MRD) take a look at tailor-made for dogs, heralding a brand new chapter in veterinary most cancers administration. Launching on March 5, 2024, this pioneering take a look at gives a novel method for veterinarians and canine house owners to detect early indicators of most cancers relapse and monitor the illness with unprecedented precision. K9-LiquiDX stands out by detecting minuscule remnants of most cancers cells post-treatment, which typical strategies may overlook, thus promising to remodel most cancers look after our canine associates.
Crafted by a crew of eminent researchers and veterinary most cancers specialists, K9-LiquiDX employs cutting-edge molecular diagnostic methods to identify the slightest indications of most cancers recurrence. Its excessive sensitivity makes it a useful asset for early intervention and customised remedy plans, signifying a significant development in monitoring remedy efficacy and modifying approaches to higher serve our pets.
Key Advantages of K9-LiquiDX embody:
- Early Relapse Detection: Offers veterinarians the potential to determine most cancers relapse at its nascent stage, probably earlier than the looks of scientific indicators.
- Precision Cancer Monitoring: Delivers complete insights into the most cancers’s development and remedy response, facilitating extra tailor-made and efficient administration.
- Enhanced Treatment Strategies: Aids in making well-informed remedy modifications, which can result in improved outcomes and life high quality for canine most cancers sufferers.
Dr. Maciej Parys, CEO of Cancan Diagnostic, highlighted the importance of this innovation, saying, “K9-LiquiDX is more than just a diagnostic test; it has a potential to revolutionise how we monitor dogs with cancer and help them and their families through improvement of their quality of life. By focusing on early relapse detection and precision monitoring, we’re opening new pathways for personalised cancer care in veterinary medicine. This test is a testament to our commitment to pioneering advancements that make a real difference in the lives of pets and their owners.”
From March 5, 2024, K9-LiquiDX can be accessible to veterinary clinics all through the UK, with Cancan Diagnostic offering complete help and sources to make sure seamless integration of this take a look at into current most cancers remedy protocols.
Since its institution in 2022, Cancan Diagnostic has been a trailblazer in veterinary diagnostic improvements, aiming to raise pet healthcare by integrating the latest scientific breakthroughs and applied sciences into veterinary apply. The introduction of K9-LiquiDX reaffirms the corporate’s dedication to main the sector of veterinary oncology and bettering the wellbeing of pets globally.
